Advertisement
Screener

Dianthus Therapeutics, Inc. /DE/ (DNTH) Stock-Based Compensation

2.8 / 5 stars · 68/120 Roast Me

Dianthus Therapeutics, Inc. /DE/ Stock-Based Compensation

Dianthus Therapeutics, Inc. /DE/ (DNTH) reported Stock-Based Compensation of $22.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ShareBasedCompensation · last filed 2026-08-04

  • Dianthus Therapeutics, Inc. /DE/ share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $11.90M, a 108.52% increase year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $10.60M, a 99.47% increase year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $5.98M, a 52.58% increase year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $5.79M, a 50.89% increase year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ share-based payment arrangement, noncash expense for fiscal 2025 was $22.79M, a 76.77% increase from fiscal 2024.
  • Dianthus Therapeutics, Inc. /DE/ share-based payment arrangement, noncash expense for fiscal 2024 was $12.89M, a 344.62% increase from fiscal 2023.
  • Dianthus Therapeutics, Inc. /DE/ share-based payment arrangement, noncash expense for fiscal 2023 was $2.90M, a 91.04% increase from fiscal 2022.
  • Dianthus Therapeutics, Inc. /DE/ share-based payment arrangement, noncash expense for fiscal 2022 was $1.52M.
Period endShare-based Payment Arrangement, Noncash Expense 3 monthShare-based Payment Arrangement, Noncash Expense 3 month as first filedShare-based Payment Arrangement, Noncash Expense 6 monthShare-based Payment Arrangement, Noncash Expense 6 month as first filedShare-based Payment Arrangement, Noncash Expense 9 monthShare-based Payment Arrangement, Noncash Expense 9 month as first filedShare-based Payment Arrangement, Noncash Expense 12 monthShare-based Payment Arrangement, Noncash Expense 12 month as first filed
2026-06-30$11.90M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$22.50M
10-Q · filed 2026-08-04
$28.48M
derived: sum of 3 quarters · filed 2026-08-04
$34.27M
derived: sum of 4 quarters · filed 2026-08-04
2026-03-31$10.60M
10-Q · filed 2026-05-05
$16.58M
derived: sum of 2 quarters · filed 2026-05-05
$22.37M
derived: sum of 3 quarters · filed 2026-05-05
$28.08M
derived: sum of 4 quarters · filed 2026-08-04
2025-12-31$5.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$11.77M
derived: sum of 2 quarters · filed 2026-03-09
$17.48M
derived: sum of 3 quarters · filed 2026-08-04
$22.79M
10-K · filed 2026-03-09
2025-09-30$5.79M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$11.50M
derived: sum of 2 quarters · filed 2026-08-04
$16.82M
10-Q · filed 2025-11-05
$20.73M
derived: sum of 4 quarters · filed 2026-08-04
2025-06-30$5.71M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$11.02M
10-Q · filed 2026-08-04
$14.94M
derived: sum of 3 quarters · filed 2026-08-04
$18.78M
derived: sum of 4 quarters · filed 2026-08-04
2025-03-31$5.32M
10-Q · filed 2026-05-05
$9.23M
derived: sum of 2 quarters · filed 2026-05-05
$13.07M
derived: sum of 3 quarters · filed 2026-05-05
$16.17M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$3.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09
$7.76M
derived: sum of 2 quarters · filed 2026-03-09
$10.86M
derived: sum of 3 quarters · filed 2026-03-09
$12.89M
10-K · filed 2026-03-09
2024-09-30$3.84M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05
$6.94M
derived: sum of 2 quarters · filed 2025-11-05
$8.98M
10-Q · filed 2025-11-05
$9.70M
derived: sum of 4 quarters · filed 2025-11-05
2024-06-30$3.10M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$5.14M
10-Q · filed 2025-08-07
$5.86M
derived: sum of 3 quarters · filed 2025-08-07
$7.04M
derived: sum of 4 quarters · filed 2025-08-07
2024-03-31$2.04M
10-Q · filed 2025-05-12
$2.76M
derived: sum of 2 quarters · filed 2025-05-12
$3.94M
derived: sum of 3 quarters · filed 2025-05-12
$4.40M
derived: sum of 4 quarters · filed 2025-05-12
2023-12-31$726.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11
$1.91M
derived: sum of 2 quarters · filed 2025-03-11
$2.37M
derived: sum of 3 quarters · filed 2025-03-11
$2.90M
10-K · filed 2025-03-11
2023-09-30$1.18M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$1.64M
derived: sum of 2 quarters · filed 2024-11-07
$2.17M
10-Q · filed 2024-11-07
$2.69M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30$462.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$995.00K
10-Q · filed 2024-08-08
$922.00K
10-Q · filed 2023-08-03
$1.51M
derived: sum of 3 quarters · filed 2024-08-08
-$1.24M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31$533.00K
10-Q · filed 2024-05-09
$506.00K
10-Q · filed 2023-05-15
$1.05M
derived: sum of 2 quarters · filed 2024-05-09
-$1.70M
derived: sum of 3 quarters · filed 2024-05-09
$146.00K
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$513.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
-$2.23M
derived: sum of 2 quarters · filed 2024-03-21
-$387.00K
derived: sum of 3 quarters · filed 2024-03-21
$1.52M
10-K · filed 2024-03-21
$7.02M
10-K · filed 2023-03-23
2022-09-30-$2.75M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$900.00K
derived: sum of 2 quarters · filed 2023-11-09
$1.00M
10-Q · filed 2023-11-09
$5.26M
10-Q · filed 2022-11-03
-$7.06M
derived: sum of 4 quarters · filed 2023-12-21
2022-06-30$1.84M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03
$3.75M
10-Q · filed 2023-08-03
-$4.31M
derived: sum of 3 quarters · filed 2023-12-21
-$513.00K
derived: sum of 4 quarters · filed 2023-12-21
2022-03-31$1.91M
10-Q · filed 2023-05-15
-$6.16M
derived: sum of 2 quarters · filed 2023-12-21
-$2.36M
derived: sum of 3 quarters · filed 2023-12-21
-$224.00K
derived: sum of 4 quarters · filed 2023-12-21
2021-12-31-$8.06M
derived: 8-K 12 month − 10-Q 9 month · filed 2023-12-21
-$4.26M
derived: sum of 2 quarters · filed 2023-12-21
-$2.13M
derived: sum of 3 quarters · filed 2023-12-21
$63.00K
8-K · filed 2023-12-21
$10.31M
10-K · filed 2022-03-08
2021-09-30$3.80M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$5.93M
derived: sum of 2 quarters · filed 2022-11-03
$8.13M
10-Q · filed 2022-11-03
$10.46M
derived: sum of 4 quarters · filed 2022-11-03
2021-06-30$2.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$4.33M
10-Q · filed 2022-08-04
$6.66M
derived: sum of 3 quarters · filed 2022-08-04
$9.02M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31$2.19M
10-Q · filed 2022-05-16
$4.52M
derived: sum of 2 quarters · filed 2022-05-16
$6.89M
derived: sum of 3 quarters · filed 2022-05-16
$9.39M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$2.33M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08
$4.70M
derived: sum of 2 quarters · filed 2022-03-08
$7.20M
derived: sum of 3 quarters · filed 2022-03-08
$9.94M
10-K · filed 2022-03-08
2020-09-30$2.37M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
$4.87M
derived: sum of 2 quarters · filed 2021-11-04
$7.61M
10-Q · filed 2021-11-04
$9.67M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30$2.50M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$5.24M
10-Q · filed 2021-08-05
$7.31M
derived: sum of 3 quarters · filed 2021-08-05
$10.07M
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$2.74M
10-Q · filed 2021-05-06
$4.80M
derived: sum of 2 quarters · filed 2021-05-06
$7.56M
derived: sum of 3 quarters · filed 2021-05-06
$10.16M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31$2.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03
$4.82M
derived: sum of 2 quarters · filed 2021-03-03
$7.42M
derived: sum of 3 quarters · filed 2021-03-03
$10.00M
10-K · filed 2021-03-03
2019-09-30$2.76M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$5.36M
derived: sum of 2 quarters · filed 2020-11-05
$7.94M
10-Q · filed 2020-11-05
$10.49M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$2.60M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
$5.18M
10-Q · filed 2020-08-06
$7.73M
derived: sum of 3 quarters · filed 2020-08-06
$11.40M
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31$2.58M
10-Q · filed 2020-05-07
$5.13M
derived: sum of 2 quarters · filed 2020-05-07
$8.80M
derived: sum of 3 quarters · filed 2020-05-07
$11.86M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31$2.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03
$6.23M
derived: sum of 2 quarters · filed 2020-03-03
$9.28M
derived: sum of 3 quarters · filed 2020-03-03
$10.70M
10-K · filed 2020-03-03
2018-09-30$3.68M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13
$6.73M
derived: sum of 2 quarters · filed 2019-11-13
$8.15M
10-Q · filed 2019-11-13
$8.93M
derived: sum of 4 quarters · filed 2020-03-03
2018-06-30$3.05M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
$4.48M
10-Q · filed 2019-08-08
$5.25M
derived: sum of 3 quarters · filed 2020-03-03
$5.81M
derived: sum of 4 quarters · filed 2020-03-03
2018-03-31$1.43M
10-Q · filed 2019-05-09
$2.20M
derived: sum of 2 quarters · filed 2020-03-03
$2.76M
derived: sum of 3 quarters · filed 2020-03-03
2017-12-31$773.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-03
$1.34M
derived: sum of 2 quarters · filed 2020-03-03
$2.26M
10-K · filed 2020-03-03
2017-09-30$565.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$1.49M
10-Q · filed 2018-11-08
2017-06-30$921.00K
10-Q · filed 2018-08-09
2016-12-31$662.00K
10-K · filed 2019-03-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
Erasca, Inc. (ERAS)United States$5.073B-19.96
PTC THERAPEUTICS, INC. (PTCT)United States$5.199B-177.07
Veradermics, Inc (MANE)United States$4.839B
Gossamer Bio, Inc. (GOSS)United States$5.355B-0.65
Cogent Biosciences, Inc. (COGT)United States$5.450B-17.61
Oruka Therapeutics, Inc. (ORKA)United States$5.663B-43.76
Edgewise Therapeutics, Inc. (EWTX)United States$4.470B-22.23
Travere Therapeutics, Inc. (TVTX)United States$5.712B-123.10
Mirum Pharmaceuticals, Inc. (MIRM)United States$5.798B-8.81
Viking Therapeutics, Inc. (VKTX)United States$4.287B-8.51